Serina Therapeutics (NYSEAMERICAN:SER) Trading Down 1.8% – Time to Sell?

Serina Therapeutics, Inc. (NYSEAMERICAN:SER)’s share price dropped 1.8% during trading on Friday . The company traded as low as $2.64 and last traded at $2.80. 75,950 shares changed hands during mid-day trading, an increase of 69% from the average session volume of 44,893 shares. The stock had previously closed at $2.85.

Wall Street Analysts Forecast Growth

Separately, BTIG Research started coverage on shares of Serina Therapeutics in a report on Wednesday, July 1st. They set a “buy” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $8.00.

Serina Therapeutics Trading Down 1.8%

The firm has a market cap of $42 million, a P/E ratio of -1.48 and a beta of 1.11. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.18 and a current ratio of 4.18. The firm has a fifty day moving average of $2.09 and a 200-day moving average of $2.02.

Serina Therapeutics (NYSEAMERICAN:SER) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) EPS for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.